Progressive Spondyloepimetaphyseal Dysplasia-short Stature-short Fourth Metatarsals-intellectual Disability Syndrome

Key Findings

Finding 1 — SEMD-FADA is caused by biallelic loss-of-function RSPRY1 variants (autosomal recessive)

The genetic basis of the disease was established by combined autozygome/exome analysis of four affected siblings from a consanguineous Saudi family, which identified a homozygous frameshift mutation in RSPRY1 undergoing nonsense-mediated decay (NMD). A simplex case from Peru carried a homozygous likely-pathogenic missense variant in the same gene, confirming allelic causation (PMID: 26365341).

"Combined autozygome/exome analysis identified a homozygous frameshift mutation in RSPRY1 with resulting nonsense-mediated decay." — PMID: 26365341

Two additional families subsequently broadened the allelic spectrum, harbouring a homozygous c.377delT (p.Ile126fs*) frameshift in exon 2 and a homozygous splice-site c.516+2T>A variant at the exon 4/intron 4 boundary (PMID: 30063090).

"Whole exome sequencing revealed a novel homozygous [c.377delT] [p.Ile126fs*] frameshift mutation at exon 2 in one family, while Sanger sequencing revealed a novel homozygous splice site mutation [c.516+2T>A] at exon 4/intron 4 border of RSPRY1 in the other family." — PMID: 30063090

The recurrence in consanguineous pedigrees with homozygous truncating and splice variants firmly supports an autosomal-recessive, loss-of-function disease mechanism.

Finding 2 — Core and expanded clinical phenotype

The index family (4 siblings) and the Peruvian case defined the recognizable phenotypic tetrad: progressive spondyloepimetaphyseal dysplasia, short stature, facial dysmorphism, short fourth metatarsals, and intellectual disability (PMID: 26365341).

"comprising progressive spondyloepimetaphyseal dysplasia, short stature, facial dysmorphism, short fourth metatarsals, and intellectual disability" — PMID: 26365341

Delineation of five additional individuals expanded the skeletal hallmarks and clarified that most patients are normocephalic and that intellectual disability is variable rather than obligate. One patient had a cemento-ossifying fibrous lesion of the maxilla (PMID: 30063090).

"The skeletal hallmarks include (a) mild spondylar dysplasia, (b) epimetaphyseal dysplasia of the long bones associated with coxa vara and genu valgum, (c) brachymesophalangy with cone-shaped epiphyses, and (d) craniosynostosis." — PMID: 30063090

Finding 3 — Pathogenesis involves TGF-β signaling dysregulation and ECM/growth-factor disruption

A 2025 functional study framed the disease within a broader class of skeletal dysplasias that arise from disrupted extracellular-matrix dynamics and growth-factor-dependent signaling, implicating RSPRY1 — a protein with RING and SPRY domains — in bone development and connecting its loss to TGF-β pathway dysregulation (PMID: 39940902).

"RSPRY1, a secreted protein with RING and SPRY domains, has been implicated in bone development" — PMID: 39940902

"often arise due to disruptions in extracellular matrix (ECM) dynamics and growth factor-dependent signaling pathways" — PMID: 39940902

Finding 4 — RSPRY1 loss causes constitutive, SMAD3-dependent TGF-β activation with ECM dysregulation

Transcriptomic analysis of fibroblasts from patients with homozygous RSPRY1 mutations showed significant enrichment of TGF-β signaling and ECM-related pathways, with SMAD2 and SMAD3 showing the highest transcription-factor enrichment and key effector genes SMAD3, COL1A1, and TRPV4. RSPRY1-knockout fibroblasts exhibited enhanced motility in wound-healing assays, a phenotype abrogated in RSPRY1+SMAD3 double-knockout cells — demonstrating SMAD3-dependence. A limited response to exogenous TGF-β in RSPRY1-deficient cells indicated the pathway was already constitutively active (PMID: 39940902).

"RSPRY1, a secreted protein with RING and SPRY domains, has been implicated in bone development" — PMID: 39940902

This is the pivotal mechanistic finding: RSPRY1 normally restrains TGF-β/SMAD3 signaling, and its loss unleashes constitutive, SMAD3-driven activation that dysregulates ECM production in bone-forming cells.

Finding 5 — Expanded variant/phenotype spectrum: novel p.Cys551Tyr missense and joint dislocation

Two Indian sisters presenting with short stature, facial dysmorphism, progressive vertebral defects, small epiphyses, cupping and fraying of metaphyses, brachydactyly, and short metatarsals were found to carry a homozygous missense variant c.1652G>A; p.(Cys551Tyr) in RSPRY1. Joint dislocation was reported as a novel clinical feature of the condition (PMID: 38562122).

"Two siblings presenting with short stature, facial dysmorphism, progressive vertebral defects, small epiphysis, cupping and fraying of metaphyses, brachydactyly, and short metatarsals harbored a homozygous missense variant c.1652G>A;p.(Cys551Tyr) in the RSPRY1 gene." — PMID: 38562122

"We observed joint dislocation as a novel clinical feature of this condition." — PMID: 38562122

Finding 6 — Exact index variants and detailed multisystem phenotype including progressive loss of ambulation

Faden et al. (2015) identified in the consanguineous Saudi family a homozygous 1-bp duplication c.1279dupA (p.Thr427AsnfsTer10) that segregated fully with disease and was absent from 650 Saudi control exomes and ExAC; the Peruvian boy carried homozygous c.121G>T (p.Gly41Cys / G41C) at a conserved residue (PMID: 26365341; OMIM #616723).

"Combined autozygome/exome analysis identified a homozygous frameshift mutation in RSPRY1 with resulting nonsense-mediated decay." — PMID: 26365341

The OMIM clinical synopsis proband — a 13-year-old girl — showed delayed motor milestones, walked at 5 years then progressively lost ambulation and became wheelchair-bound, generalized hypotonia, microcephaly, flattened occiput, malar hypoplasia, low-set small ears, short neck, short hands, rocker-bottom feet with overriding toes, genu valgum, and scoliosis. Skeletal survey documented generalized osteopenia, delayed bone age, copper-beaten skull with premature suture closure (craniosynostosis), short metacarpals, platyspondyly, anterior vertebral wedging and posterior scalloping, thoracolumbar scoliosis, narrow pelvis, bilateral coxa vara, short/slender long bones, small epiphyses, metaphyseal cupping/fraying (tibia/fibula), slipped capital femoral epiphyses, short femoral neck, and distal femoral bowing.

Finding 7 — RSPRY1 orthologs, expression pattern, and knockout mouse resources

RSPRY1 is conserved 1:1 across human (NCBI Gene 89970; 16q13), mouse (Rspry1, MGI:1914860), rat, and zebrafish (rspry1, NCBI 565154; ENSDARG00000062558). The human protein shares 97% amino-acid identity with mouse and rat and contains a SPRY domain plus a putative C3HC4-type (RING) zinc finger. Faden et al. showed Rspry1 is expressed in mouse limb-bud mesenchyme from E12.5 and, at E18.5 (primary ossification), is abundant in developing endochondral bones and skeletal muscle (with signal also in heart, kidney, and brain), localizing strongly to osteoblasts and osteocytes, minimally to chondrocytes, and prominently in perichondrium/periosteum (PMID: 26365341).

"we detect strong RSPRY1 protein localization in murine embryonic osteoblasts and periosteal cells during primary endochondral ossification, consistent with a role in bone development" — PMID: 26365341

Targeted knockout alleles exist (Rspry1^tm1(KOMP)Wtsi, MGI:4419609; Rspry1^tm1Lex, MGI:5007310) with corresponding IMPC/IMSR strains, but no published mouse model recapitulating the human skeletal dysplasia phenotype was identified.

Mechanistic Model / Interpretation

RSPRY1 integrates into the growth-factor circuitry that governs endochondral ossification. The convergent genetic, transcriptomic, and functional data support the following causal chain:

Biallelic LOF RSPRY1 variants (frameshift/splice/missense)
│  (NMD of truncating alleles → loss of protein)
▼
Loss of RSPRY1 negative regulation of TGF-β pathway
│
▼
Constitutive, SMAD3-dependent TGF-β/SMAD activation
   (↑ SMAD2/SMAD3 TF activity; ↑ SMAD3, COL1A1, TRPV4)
│
▼
Dysregulated ECM dynamics in osteoblasts / periosteum / perichondrium
   (bone-forming cells, minimal chondrocyte expression)
│
▼
Disordered endochondral ossification
│
▼
Progressive spondyloepimetaphyseal dysplasia, short stature,
short 4th metatarsals, craniosynostosis, coxa vara/genu valgum,
SCFE, scoliosis, joint dislocation ± intellectual disability

Upstream vs downstream. The upstream trigger is loss of the RSPRY1 protein (a RING+SPRY E3-ligase-like/adaptor molecule). The proximate downstream node is de-repression of TGF-β/SMAD3, and the terminal downstream events are ECM misregulation and defective bone matrix deposition during endochondral ossification.

Cell types and processes. Affected cells are principally osteoblasts (CL:0000062) and osteocytes (CL:0000137) plus periosteal/perichondrial fibroblasts; chondrocytes are relatively spared at the expression level. Relevant biological processes include endochondral ossification (GO:0001958), ossification (GO:0001503), TGF-β receptor signaling pathway (GO:0007179), SMAD protein signal transduction (GO:0060395), extracellular matrix organization (GO:0030198), and regulation of ossification (GO:0030278). Cellular components implicated include the RING-type zinc finger / ubiquitin-ligase machinery and the extracellular matrix (GO:0031012).

Ontology anchors. MONDO: SEMD Faden–Alkuraya type (mapped to OMIM #616723). Gene: HGNC RSPRY1. UBERON anatomical sites: vertebral column (UBERON:0001130), long bone epiphysis (UBERON:0001438) and metaphysis (UBERON:0004958), metatarsal bone (UBERON:0001448), cranial suture (UBERON:0007712), femoral neck. CHEBI/pathway: TGF-β (protein signal), collagen type I (COL1A1). NCIT interventions are limited to supportive/orthopedic categories (see Treatment).

Evidence Base

The four RSPRY1-specific papers (26365341, 30063090, 38562122, 39940902) are mutually reinforcing: gene discovery, phenotype expansion, allelic expansion, and mechanism, respectively. The cohort study (39706863) situates the disorder among predominantly autosomal-recessive skeletal dysplasias in consanguineous populations, and the deletion case (27230627) provides orthogonal support that RSPRY1 dosage loss produces skeletal defects.

Epidemiology, Inheritance, Diagnostics, Prognosis, Treatment & Prevention (Consolidated)

Epidemiology & inheritance. SEMD-FADA is ultra-rare with only a handful of families reported worldwide (Saudi Arabia, Peru, Turkey, India); precise prevalence/incidence figures are unavailable (Orphanet lists it without a firm prevalence estimate). Inheritance is autosomal recessive; reported cases arise in consanguineous unions, consistent with homozygous variants identified by autozygosity mapping. Penetrance appears complete for the skeletal phenotype among biallelic carriers, with variable expressivity particularly for intellectual disability and head circumference. No founder variant has been established, though recurrence in specific populations reflects consanguinity.

Diagnostics. Diagnosis rests on radiographic skeletal survey (platyspondyly, epimetaphyseal changes, coxa vara, genu valgum, cone-shaped epiphyses, craniosynostosis, short 4th metatarsals) combined with molecular confirmation of biallelic RSPRY1 variants via whole-exome/whole-genome sequencing or targeted skeletal-dysplasia gene panels; single-gene testing/Sanger confirmation and segregation analysis complete the workup. Differential diagnoses include other spondyloepimetaphyseal dysplasias and cono-brachydactyly syndromes. No specific serum/urine biomarker exists.

Prognosis. The disorder is progressive: short stature, worsening epimetaphyseal disease, slipped capital femoral epiphyses, and scoliosis accrue over childhood, and at least one patient progressively lost ambulation and became wheelchair-bound. Life expectancy has not been reported as significantly shortened; morbidity is driven by orthopedic disability and, where present, cognitive impairment.

Treatment. There is no disease-specific or curative therapy. Management is supportive and multidisciplinary: orthopedic surgery (for coxa vara, SCFE, scoliosis, joint dislocation), craniosynostosis surgery where indicated, physical/occupational therapy and mobility aids, developmental and educational support for intellectual disability, and genetic counseling for consanguineous families. Relevant NCIT categories are limited to supportive/orthopedic interventions (e.g., NCIT orthopedic surgical procedure, physical therapy, genetic counseling). The mechanistic identification of constitutive TGF-β/SMAD3 activation raises the theoretical possibility of TGF-β pathway inhibition as a future targeted strategy, but this remains entirely experimental.

Prevention. Primary prevention is limited to genetic counseling, carrier testing in at-risk families, and options such as prenatal diagnosis or preimplantation genetic testing once the familial variant is known. Public-health counseling regarding consanguinity is relevant in populations where the disorder recurs.

Other species / model organisms. Rspry1 is conserved in mouse, rat, and zebrafish. Off-the-shelf knockout mouse alleles (Rspry1^tm1(KOMP)Wtsi; Rspry1^tm1Lex) are available through IMPC/IMSR, but no published model recapitulates the human skeletal dysplasia, and no naturally occurring animal disease has been described.

Limitations and Knowledge Gaps

1. Very small case count. Fewer than ~15 molecularly confirmed individuals are reported, so genotype–phenotype correlations, penetrance estimates, and natural-history data are provisional. No formal prevalence/incidence exists.
2. Mechanism largely from patient fibroblasts. The constitutive SMAD3-dependent TGF-β activation was demonstrated in dermal fibroblasts and knockout fibroblast lines (PMID: 39940902), not in primary human osteoblasts/chondrocytes; whether the same circuit operates identically in the growth plate in vivo is inferred, not proven.
3. No phenotype-recapitulating animal model. Although knockout alleles exist, none has been reported to reproduce the human skeletal dysplasia, leaving in-vivo mechanism and therapeutic testing unaddressed.
4. Protein biochemistry incomplete. RSPRY1 is variably described as "secreted" and as a RING+SPRY protein; its precise molecular activity (e.g., E3 ubiquitin ligase substrate specificity toward TGF-β/SMAD components) is not experimentally resolved.
5. Variant interpretation. Missense variants (p.Gly41Cys, p.Cys551Tyr) require ongoing ACMG re-evaluation and functional validation; allele frequencies in gnomAD for these are effectively absent/ultra-rare, consistent with pathogenicity but not exhaustively characterized here.
6. Intellectual disability mechanism unexplained. Whether ID reflects a direct neuronal role of RSPRY1 (expressed in brain) or a secondary consequence remains unknown.

Proposed Follow-up Experiments / Actions

1. Generate a conditional/global Rspry1-knockout mouse and phenotype the skeleton (micro-CT of long bones, spine, skull sutures; growth-plate histology) to test whether it recapitulates SEMD, coxa vara, craniosynostosis, and SCFE.
2. Assay TGF-β/SMAD3 signaling directly in patient- and CRISPR-derived osteoblasts/chondrocytes (phospho-SMAD3 Western blot, SMAD-responsive luciferase reporters, RNA-seq) to confirm the fibroblast findings in bone-lineage cells.
3. Test pharmacologic TGF-β/SMAD3 inhibition (e.g., ALK5/TGFBR1 inhibitors) in RSPRY1-null cellular and, if validated, murine models to establish proof-of-concept for a targeted therapy.
4. Define RSPRY1 biochemistry: determine whether the RING domain confers E3 ubiquitin-ligase activity and identify SMAD-pathway substrates via IP–mass spectrometry; localize the protein (secreted vs intracellular).
5. Establish an international patient registry to capture natural history, ambulation trajectory, craniosynostosis outcomes, and quality-of-life measures, and to refine penetrance/expressivity.
6. Functionally validate missense variants (p.Gly41Cys, p.Cys551Tyr) in expression/degradation and signaling assays to firm up ACMG classification.
7. Screen contiguous-gene-deletion cohorts (16q12–q21) for skeletal features to quantify the contribution of RSPRY1 dosage (PMID: 27230627).

Consensus Answer

Spondyloepimetaphyseal dysplasia, Faden–Alkuraya type (SEMD-FADA; OMIM #616723, Orphanet ORPHA:457395) is an ultra-rare autosomal-recessive skeletal dysplasia caused by biallelic loss-of-function variants in RSPRY1 (16q13; a 576-aa RING+SPRY protein). Its core phenotype is progressive spondyloepimetaphyseal dysplasia with short stature, short fourth metatarsals, facial dysmorphism, and intellectual disability, plus craniosynostosis, coxa vara/genu valgum, slipped capital femoral epiphyses, scoliosis, and sometimes progressive loss of ambulation; pathogenesis involves constitutive, SMAD3-dependent TGF-β/ECM signaling dysregulation in osteoblasts and perichondrium during endochondral ossification. Management is supportive and multidisciplinary, as no disease-specific therapy exists.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMID:30063090 (abstract only): "Whole exome sequencing revealed a novel homozygous [c.377delT] [p.Ile126fs*] frameshift mutation at exon 2 in one family, while Sanger sequencing revealed a novel homozygous splice site mutation [c.516+2T>A] at exon 4/intron 4 border of RSPRY1 in the other family."
• closest text in source: "Whole exome sequencing revealed a novel homozygous [c.377delT] [p.Ile126fs*] frameshift mutation at exon 2 in one family, while Sanger sequencing revealed a novel homozygous splice site mutation [c.516+2T>A] at exon 4/intron 4 border of RSPRY1 in the other family"